| 摘要 |
The invention relates to a gaseous medication containing xenon, preferably in an amount of less than 75% by volume, for use by inhalation, in combination with at least one NMDA receptor antagonist in the form of a liquid or solid, in particular memantine, for treating, slowing or preventing neurological deterioration consequent upon a neurodegenerative disease, in particular Alzheimer's disease, in a human patient. |
